Martin Jensen
Founder bei EXPRES2ION BIOTECH HOLDING AB
Profil
Martin Roland Jensen is the founder and Chairman of ExpreS2ion Biotechnologies ApS since 2009 and Expres2ion Biotech Holding AB since 2010.
He is also the founder of Unikum Therapeutics ApS, Medic Advice ApS, and Martin Roland Holding ApS.
Dr. Jensen's former jobs include being the Chief Executive Officer of CytoVac AS, and a Principal at Pharmexa A, T-cellic A, and Scancell A.
He received his undergraduate and doctorate degrees from the University of Copenhagen in 1994.
Aktive Positionen von Martin Jensen
| Unternehmen | Position | Beginn |
|---|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Founder | 01.01.2010 |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Founder | 01.01.2009 |
| Medic Advice ApS | Chief Executive Officer | - |
| Martin Roland Holding ApS | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Martin Jensen
| Unternehmen | Position | Ende |
|---|---|---|
| Unikum Therapeutics ApS | Founder | - |
CytoVac AS
 CytoVac AS BiotechnologyHealth Technology CytoVac AS manufactures pharmaceuticals. The private company is based in Hørsholm, Denmark. The Danish company was founded in 2008. The CEO is Lone Dahl Andersen. | Chief Executive Officer | - |
| T-cellic A/S | Corporate Officer/Principal | - |
| Scancell A/S | Corporate Officer/Principal | - |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Corporate Officer/Principal | - |
Ausbildung von Martin Jensen
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
| T-cellic A/S | |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Health Technology |
CytoVac AS
CytoVac AS BiotechnologyHealth Technology CytoVac AS manufactures pharmaceuticals. The private company is based in Hørsholm, Denmark. The Danish company was founded in 2008. The CEO is Lone Dahl Andersen. | Health Technology |
| Scancell A/S | |
| Medic Advice ApS | |
| Martin Roland Holding ApS | |
| Unikum Therapeutics ApS |
